Ref ID: 119.1
----- Original Message ----From: "Reich Adam" <adi_medicalis@go2.pl>
To: <anr2004@neuroblastoma.org>
Sent: Tuesday, January 27, 2004 11:00 AM
Subject: Abstract send
>
> -Abstract number 2 :
>
> -Author 1 :
> - -First name: ............. Bernarda
> - -Middle Initial: .............
> - -Family Last name: ............. Kazanowska
> - -Affiliation: ............. Department of Paediatric Haematology and
Oncology, University of Medicine, Wroc&#322;aw
> - -Degree: ............. MD, PhD
> -Author 2 :
> - -First name: ............. Adam
> - -Middle Initial: .............
> - -Family Last name: ............. Reich
> - -Affiliation: ............. Department of Paediatric Haematology and
Oncology, University of Medicine, Wroc&#322;aw
> - -Degree: ............. MD
> -Author 3 :
> - -First name: ............. Ewa
> - -Middle Initial: .............
> - -Family Last name: ............. Drozynska
> - -Affiliation: ............. Department of Paediatry, Haematology,
Oncology and Endocrinology, University of Medicine, Gdansk
> - -Degree: ............. MD, PhD
> -Author 4 :
> - -First name: ............. Iwona
> - -Middle Initial: .............
> - -Family Last name: ............. Kardas
> - -Affiliation: ............. Department of Biology and Genetics,
University of Medicine, Gdansk
> - -Degree: ............. PhD
> -Author 5 :
> - -First name: ............. Alicja
> - -Middle Initial: .............
> - -Family Last name: ............. Chybicka
> - -Affiliation: ............. Department of Paediatric Haematology and
Oncology, University of Medicine, Wroc&#322;aw
> - -Degree: ............. MD, PhD
>
> -Author 6 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Author 7 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Author 8 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Author 9 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Author 10 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Author 11 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Author 12 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Author 13 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Author 14 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Author 15 :
> - -First name: .............
> - -Middle Initial: .............
> - -Family Last name: .............
> - -Affiliation: .............
> - -Degree: .............
>
> -Department: ............. Department of Paediatric Haematology and
Oncology
> -Institution: ............. University of Medicine
> -City: ............. Wroclaw
> -State: .............
> -Country: ............. Poland
> -Postal code: ............. 50-345
>
> -Title(s):
> - - -PROGNOSTIC VALUE OF TELOMERASE ACTIVITY IN NEUROBLASTOMA LIKE TUMOURS
>
> -Abstract(s):
> - - -Background: The presence of activated telomerase in neoplasm cells
prevents from telomere shortening and causes the neoplasm cell immortal.
> Aims: The aim of the study was the evaluation of the influence of
telomerase activity on prognosis in neuroblastoma like tumours.
> Patients: 33 tissue samples obtained from 30 patients aged between 1 and
75 months (19 males and 11 females) were analysed. Histologically
neuroblastoma was diagnosed in 24 patients (80%), ganglioneuroblastoma in 4
(13,3%) and ganglioneuroma in 2 (6,7%) cases.
> Methods: Tissue samples were frozen immediately after the biopsy and were
stored in -80ºC until the analysis. Two independent methods were used for
telomerase activity evaluation: Telomerase Repeat Amplification Protocol
(TRAP) and ELISA method.
> Results: Telomerase activity was stated in 9 tissue samples of primary
tumour, in the regional lymph nodes infiltrated by neoplasm cells and in the
metastatic relapse in mediastinum in single cases. Neuroblastoma with
telomerase activity presented more advanced disease and also more often the
prognostically unfavourable MYCN amplification was stated. Patients with
telomerase activity had significantly poorer outcome in comparison to
patients without telomerase activity (5-year EFS 0,61 and 0,15 respectively;
p=0,01).
> Conclusions: The assessment of telomerase activity could be helpful in the
stratification and the choice of the optimal therapy. The influence of
telomerase on clinical outcome advocates its pathogenetic role in
neuroblastoma, so the enzyme could be a possible target for new antitumour
drugs inhibiting it.
>
>
> -Presentation mode(s):
> - - -poster_presentation
>
> - - -- - -- - -- - >
>